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Abstract
Rhodococcus is an emerging cause of opportunistic infection in immunocompromised patients, most commonly causing
cavitary pneumonia. It has rarely been reported as a cause of isolated bacteremia. However, the relationship between
bacteremia and central venous catheter is unknown. Between 2002 and 2010, the characteristics and outcomes of
seventeen cancer patients with Rhodococcus bacteremia and indwelling central venous catheters were evaluated.
Rhodococcus bacteremias were for the most part (94%) central line-associated bloodstream infection (CLABSI). Most of the
bacteremia isolates were Rhodococcus equi (82%). Rhodococcus isolates formed heavy microbial biofilm on the surface of
polyurethane catheters, which was reduced completely or partially by antimicrobial lock solution. All CLABSI patients had
successful response to catheter removal and antimicrobial therapy. Rhodococcus species should be added to the list of
biofilm forming organisms in immunocompromised hosts and most of the Rhodococcus bacteremias in cancer patients are
central line associated.
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Introduction
Rhodococcus has emerged as an opportunistic pathogen in
immunocompromised patients [1,2]. The name of Rhodococcus
derives from the characteristic salmon- pink to red colored and
teardrop shaped mucoid colonies that vary in size from 2 mm to
4 mm after 4 days of growth on solid media. Rhodococci are generally
non-motile, intracellular aerobic, gram-positive, weakly acid-fast
coccobacilli [3,4]. Although inhalation of infected aerosols and dust
particles seems to be the predominant form of transmission of
Rhodococcus infection (.80% of cases of Rhodococcus have pulmonary
involvement), Rhodococcus can also be acquired by direct inoculation
into the skin and mucous membranes [5,6]. Other routes of
acquisition include nosocomial spread, human colonization and
person to person transmission [7]. Furthermore, epidemiological
exposure to livestock or farming environment is strongly associated
with Rhodococcus infection in immunocompromised patients [8].
Rhodococcus bacteremia is relatively rare and was perceived to be
invisibly associated with concomitant cavitary lung infection [6].
Isolated bacteremiaandCLABSI duetoRhodococcushavebeenrarely
reported in the literature and only described in immunocompro-
mised patients [6,9,10,11,12,13,14,15]. The first objective of this
study was to describe the clinical characteristics and the source and
outcomes of Rhodococcus bacteremia in cancer patients. The second
objective aimed to investigate the effect of Rhodococcus on the biofilm
formation on central venous catheters (CVC) in a laboratory model
and whether Rhodococcus organisms embedded in biofilm could be
eradicated by an effective antimicrobial lock solution.
Results
Descriptive statistics of patient demographics were conducted on
seventeen cancer patients identified during the study period (Table
S1). All patients had CVC in place at least 48 hours before the
clinical presentation and blood culture sample collection. Rhodococcus
bacteremia in our cancer patient population presented mainly with
CLABSI; 16 patients (94%) had CLABSI (six of the 16 CLABSI
patients fulfilled all the criteria for definite CRBSI) (Table S2) and
only one patient (6%) had disseminated Rhodococcus bacteremia, with
pneumonia as the most likely source. (Rhodococcus equi was recovered
from bronchoalveolar lavage fluid.) Only the patient with dissem-
inated Rhodococcus bacteremia with lung involvement spent11 daysin
the intensive care unit for septic shock, while the other 16 patients
with Rhodococcus CLABSI presented with few clinical manifestations
only, with fever being the most common clinical complaint.
The majority of patients (65%) were initiated on combination
therapy, while six patients (35%) were treated with monotherapy.
Of the 17 patients, 88% underwent CVC removal, after a median
duration of 43 days from the day of bacteremia (range 1–287).
Only 5 patients (29%) had their CVC removed within 10 days.
Patients were treated with antibiotics for a median of 11days
(range, 1–90), with abatement of fever in less than 72 hours. The
patients had resolution of their bacteremia after a median duration
of 5 days (range 1–47 days). The median duration of stay in the
hospital was 10 days (range, 2–157).
All Rhodococcus isolates were consistently susceptible to gentami-
cin and tigecycline; however, they had varying susceptibility rates
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(91%), trimethoprim-sulfamethoxazole (88%), rifampin (88%),
linezolid (87%), tetracycline (82%), and azithromycin (33%) and
demonstrated resistance to all beta lactam antibiotics tested
(penicillin, ampicillin sulbactam, and oxacillin).
Evaluation of biofilm formation and efficacy of
antimicrobial lock solution
All Rhodococcus isolates (equi and non-equi) adhered to the surface
of polyurethane CVC to create extensive biofilm matrix.
Quantitative culture of disrupted biofilm formation showed
significant biofilm formation of approximately 10
6 colony forming
units (CFU) per 1 cm segments (range 1.09610
6–1.76610
7 CFU/
segment) for R. equi, Rhodococcus spp, and R. corynebacterioides.
(Figure 1) There was no significant difference (p=0.13) in the
amount of biofilm produced by R. equi (median CFU/1 cm
segment: 3.85610
6) when compared to the non-equi Rhodococcus
isolates (median CFU/1 cm segment: 9.63610
5).
Of the three solutions tested trimethoprim EDTA+EtOH was
significantly more effective in preventing biofilm formation
when compared to other solutions and to control (all p-
values,0.01) and showed complete kill when exposed to all
Rhodococcus isolates indicating that the trimethoprim EDTA +
EtOH lock solution is able to penetrate and eradicate the
Rhodococcus in biofilm. A 1–2 log reduction was seen with the
remaining lock solutions (VancoHeparin and MethBlue) indi-
cating limited biofilm penetration and activity against Rhodo-
coccus biofilm. (Figure 2)
Analysis by scanning electron microscopy at 50006magnifica-
tion showed extensive biofilm formation with visible Rhodococcus
bacterium present along with biofilm matrix. (Figure 3).
Discussion
Rhodococcus CLABSI in cancer patients with advanced level of
immunosuppression is not well studied and whether the CVC
should be suspected as the source of a Rhodococcus bacteremia in the
absence of apparent organ involvement has not yet been
investigated.
In this study we demonstrated that Rhodococcus forms heavy
biofilm on the surfaces of CVC polymers. Most of the Rhodococcus
bacteremias in our cancer patients were catheter-related. Only one
patient had disseminated Rhodococcus infection with cavitary lung
disease and secondary Rhodococcus bacteremia. Therefore, despite
their rarity, Rhodococcus species should be included in the
differential diagnosis of organisms causing CLABSI in immuno-
compromised patients with advanced levels of immunosuppres-
sion.
Cancer patients depend immensely on intravascular access
devices and the CVCs may become the source and focus of
Rhodococcus bacteremia, given the ubiquitous presence of these
organisms in the environment and their ability to adhere to CVCs
and promote biofilm formation on the surface of the catheter.
Hand contamination with Rhodococcus at the time of CVC
manipulation may have an impact on Rhodococcus bacteremia.
Epidemiological exposure to farming environments may clearly
Figure 1. Formation of Rhodococcus biofilm on 1 cm polyurethane catheter segments. There was no significant difference in biofilm
formation on the surface of the catheter when comparing Rhodococcus non-equi and R. equi isolates (p=0.13).
doi:10.1371/journal.pone.0032945.g001
Rhodococcus Bacteremia
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information about exposures to livestock or domesticated animals
such as horses and pigs was lacking. Evidence of this Rhodococcus
biofilm formation was further shown in an in vitro biofilm model
through quantitative biofilm culture and scanning electron
microscope (Figures 1 and 3). Intraluminal colonization of the
CVC through the formation of antibiotic-resistant biofilm matrix
is the most important factor in the pathogenesis of CLABSI. The
biofilm allows Rhodococcus species to protect themselves from the
host’s defenses and create a foothold from which these organisms
can invade the bloodstream through the luminal or external
surfaces of the CVC’s intravascular segment.
Most Rhodococcus human infections have been caused by
Rhodococcus equi and only a few other species were reported to
cause infections [13,16,17,18]. This finding was confirmed by this
current study whereby Rhodococcus bacteremia in cancer patients
was caused mostly by R. equi (82%) but all species (Rhodococcus equi
and non-equi) were biofilm forming (Figure 1) leading to CLABSI.
Previous studies reported that Rhodococcus equi infection in
immunocompetent patients has a better prognosis than the disease
in immunocompromised patients with a mortality of 11% vs. 20–
55% respectively. [19,20]. Recently, Yamshchikov and colleagues
showed that R. equi-related mortality rates in organ transplant
patients was 10% [4]. Unlike these previous studies, a survival rate
of 100% was observed in Rhodococcus bacteremias in our study,
thereby stressing the better prognosis associated with CLABSI in
cancer patients even with advanced level of immune suppression.
Rhodococcus CLABSI can be managed by early initiation of
Figure 2. Efficacy of various lock solutions against clinical Rhodococcus isolates. Trimethoprim EDTA+EtOH demonstrated significant
reduction in Rhodococcus biofilm formation as compared to other solutions and to control (all p-values,0.01) with a complete kill.
doi:10.1371/journal.pone.0032945.g002
Figure 3. SEM of Rhodococcus biofilm formed on the surface of
a polyurethane catheter. Image is magnified at 50006. Extensive
Rhodococcus gram positive rods can be seen embedded and fused
together by biofilm matrix, indicated by arrows. Individual Rhodococcus
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against Rhodococcus. In addition catheter removal might improve
outcome possibly by avoiding distant recurrences and the
occurrence of deep-seated infections as if the CVC is retained,
the organism may persist and colonize the catheter.
In agreement with previous results, our finding also confirmed in
vitro activity of aminoglycosides, glycopeptides, macrolides, fluoro-
quinolones, rifampicin, tetracyclines and linezolid [21]. According
to these results, the antimicrobial sensitivity of Rhodococcus strains
causing CLABSI in cancer patients did not differ from those
previously reported. The most active in vitro antimicrobials were
tigecycline and gentamicin, followed by vancomycin, fluoroquino-
lones, TMP-SMX, rifampin, linezolid and doxycycline. Gentamicin
and glycopeptides such as vancomycin are appropriate choices.
Primary prophylaxis is not routinely recommended because no
data are available to support its efficacy and because the infection is
rare [6]. Rhodococcus bacteremia presented as a breakthrough
infectionwhile on activeantimicrobialagentsto whichtheorganism
was susceptible, such as fluoroquinolones, TMP-SMX and
vancomycin in 45% of patients. Given the fact that Rhodococcus
species can form an antibiotic-resistant multilayered biofilm matrix
in which they embed themselves, it is not surprising that all of the
breakthrough Rhodococcus bacteremias that occurred while on active
antimicrobials were CLABSI cases. Many antibiotics are ineffective
in breaking down the matrix and eradicating bacteria embedded in
biofilm [22]. This is a real therapeutic and prophylactic challenge in
the management of CVC in cancer patients. Hence, an effective
broad spectrum antimicrobial catheter lock solution with broad
spectrum activity against biofilm-forming bacteria (including
Rhodococcus) and fungi might be the best alternative strategy for the
prevention of CLABSI in cancer patients with long term indwelling
CVC [23,24] and warrants further evaluation in clinical trials.
In this current study we tested and compared the activity of
various catheter lock solutions. Vancomycin/heparin and the
novel methylene blue solution have been shown to reduce the risk
of CLABSI caused by gram positive bacteria [25,26]. However,
trimethoprim EDTA/25%ETOH has been shown to eradicate
resistant bacteria and fungi embedded in biofilm in a manner
superior to the methylene blue solution as far as their activity
against methicillin-resistant Staphylococcus aureus (MRSA), Pseudomo-
nas aeruginosa and Candida albicans in early and mature biofilm
[27,28]. Our data support these findings whereby trimethoprim-
EDTA/25% ETOH was most effective, when compared to the
other solutions, in eradicating Rhodococcus in biofilm (Figure 2).
In conclusion, Rhodococcus bacteremia in cancer patients was
mostly catheter related and responded well to short duration of
antimicrobial therapy. Since Rhodococcus organisms promote exten-
sive biofilm formation on CVC, Rhodococcus species must be included
among the causative agents of CLABSI and the indwelling CVC
should be suspected as the source of Rhodococcus bacteremia in cancer
patientswith no otherapparentsource forthe bloodstreaminfection.
Materials and Methods
Approval to conduct this study was obtained from the M. D.
Anderson Cancer Center Institutional Review Board. Upon
hospital admission, written consent was given by the patients for
their information to be stored in the hospital database and used for
research. A waiver of informed consent for this study was obtained.
Clinical characteristics
We retrospectively identified cancer patients with Rhodococcus
bacteremia by searching the microbiology laboratory database at
The University of Texas M. D. Anderson Cancer Center, Houston,
TX, (UTMDACC) from January 2002 through March 2010.
Pertinent data from patients’ medical records were abstracted
including demographic characteristics, underlying malignancies,
presence of hematopoietic stem cell transplantation, graft-versus
host disease, clinical presentation, results of laboratory tests and
imaging studies, concomitant infections, antibiotic therapy type and
duration, and patient outcome at three month follow-up.
Definitions
Neutropenia was defined as an absolute neutrophil count (ANC)
of ,500 cells/mm
3, and lymphopenia as an absolute lymphocyte
count (ALC) of ,1000 cells/mm
3. Patients with at least one set of
positive blood cultures for Rhodococcus were defined as having
Rhodococcus bacteremia. Once Rhodococcus was isolated from the
blood, it was considered as a real pathogenic organism. Central line-
associated bloodstream infection was diagnosed according to the
Centers of Disease Control and Prevention (CDC) guidelines [29].
The diagnosis of central line associated bloodstream infection
(CLABSI) was considered if the patient had a recognized pathogen
cultured from one or more blood cultures (did not include organisms
considered common skin contaminants) and no apparent source for
the bloodstream infection except the CVC. Furthermore, CLABSI
was considered as catheter-related bloodstream infection (CRBSI) if,
in addition to the CDC criteria, the Infectious Disease Society of
America (IDSA) definition criteria were also fulfilled, suggesting that
the CVC is the culprit source of the bloodstream infection [30].
These criteria consisted of the diagnosis of CLABSI as per the CDC
criteria and at least one of the following: quantitative (.10
3 CFU/
catheter segment) catheter culture, whereby the same organism was
isolated from the catheter segment and peripheral blood, or by
differential quantitative blood culture with simultaneous quantitative
blood cultures from the CVC and the peripheral blood revealing a
ratio of $3:1. The diagnosis of disseminated Rhodococcus bacteremia
required the recovery of Rhodococcus from a different organ
noncatheter-related site (expectorated sputum, endotracheal aspira-
tion, broncho-alveolar lavage, pleural effusion, lung tissue or skin) in
the setting of clinical and radiographic evidence of organ
involvement (i.e. pneumonia, skin lesions, etc.). All the patients
had a CVC in place at the time of bacteremia.
Microbiologic identification
Rhodococcus samples were isolated from clinical blood samples and
obtained from the UTMDACC clinical microbiology laboratory.
Isolates were identified on the basis of the salmon colored mucoid
morphology of colonies. Speciation for the Rhodococcus spp and R.
corynebacteroides was performed by the UTMDACC clinical microbi-
ology laboratory using the 16S rRNA gene. Rhodococcus spp. were
confirmed to be non-equi and matched with several named and
unnamed species such as EU741107, R. gordoniae W4937, R.
pyridivorans,andR.rhodochrousDSM43241.Confirmationofspeciation
of the R. equi isolates was done by PCR amplification of a 956 bp
fragment of the cholesterol oxidase gene that was determined to be
species specific to R. equi [31]. Broth micro-dilution minimal
inhibitory concentration method was used for susceptibility testing
of Rhodococcus species, according to published guidelines by the
Clinical and laboratory Standards Institute (CLSI 2003). Antimicro-
bial response was defined as resolution or improvement of clinical
manifestations, in addition to negative microbiologic findings.
Evaluation of biofilm formation and efficacy of
antimicrobial lock solution
We used a quantitative microbiological assessment and scanning
electron microscope examination to assess the biofilm formation.
Using a modified Kuhn’s model of biofilm colonization [32,33],
Rhodococcus Bacteremia
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biofilm formation.
Each isolate was tested in sextuplet. Sterile polyurethane CVC
segments were placed in 24 well tissue culture plates containing
human plasma and incubated while shaking for 24 h at 37uC. The
plasma was then replaced with 1 ml of 5.5610
5 cells/ml of
Rhodococcus inoculum and incubated while shaking for 48 h at
37uC. Prior to exposure to catheter segments the inoculum was
grown in brain heart infusion broth for 4 hrs at 37uC and diluted
to 5.5610
5 CFU/mL. The broth was then removed, and CVC
segments were washed with 1 ml of 0.9% sterile saline by shaking
at 100 rpm for 30 min at 37uC. Segments were transferred into
5 ml of 0.9% sterile saline and sonicated for 15 minutes to disrupt
biofilm. The resulting solution was then quantitatively cultured by
making serial dilutions in 0.9% sterile saline and plating on
trypticase soy agar with 5% sheep blood. All plates were incubated
inverted for 48 hrs at 37uC for growth.
To evaluate the efficacy of antimicrobial lock solutions against
Rhodococcus biofilm, all five Rhodococcus isolates (three R. equi and
two non-equi) were exposed independently and tested in sextuplet
to three antimicrobial lock solutions including, 10 mg/mL
trimethoprim+30 mg/mL CaEDTA+25% EtOH (TEDTA+E-
tOH), 1 mg/mL vancomycin+100 uL/mL heparin (VancHe-
parin), and 0.05% Methylene blue+7% Sodium Citrate+0.15%
methylparaben+0.015% propylparaben (MethBlue). Biofilm was
formed on 1 cm segments of sterile polyurethane catheters as
described above. After the washing step, segments were exposed to
the three antimicrobial lock solutions for 2 hours shaking at 37u.
Segments were then removed from lock solution, placed in 5 mL
of 0.9% sterile saline, sonicated for 15 minutes, and quantitatively
cultured as described above.
In order to visualize Rhodococcus biofilm, samples were evaluated
in duplicate using scanning electron microscopy. One centimeter
polyurethane catheter segments were exposed to Rhodococcus
isolates as above to form biofilm. Segments were then fixed with
2% glutaraldehyde, followed by fixation with osmium tetraoxide,
tannic acid, and uranyl acetate as described in previous studies
[33]. Further, a series of ethanol dehydration steps were
performed on the segments and then sputter coated with Au-Pd
(60/40 ratio) and viewed with a model XL3C Philips microscope.
Statistical Methods
Descriptive statistics were used to describe the basic features of
the clinical data in the study. Regarding biofilm data, for each
Rhodococcus isolate, the biofilm formation measured by CFU/1 cm
segment were compared among uncoated control catheters and
catheters treated with different antimicrobial lock solutions. First, a
Kruskal-Wallis test was used for comparison. If a significant result
(p,0.05) was detected, we used Wilcoxon rank sum tests for the
pairwise comparisons. The a levels of the post-hoc pairwise
comparisons were adjusted using a sequential Bonferroni adjust-
ment to control type I error. Wilcoxon rank sum test was also used
to compare biofilm formation between Rhodococcus equi and
Rhodococcus non-equi isolates. All analyses were performed using
SAS version 9.1 (SAS Institute, Cary, NC)
Supporting Information
Table S1
aCLABSI, central line associated blood stream
infection;
bGVHD, graft versus host disease;
cHSCT, hematopoi-
etic stem cell transplant;
dICU, intensive care unit;
eTMP/SMX,
trimethoprim-sulfamethoxazole
*6 patients had definite catheter-
related bloodstream infection (CRBSI)
**Viral infection comprised
Adenovirus lower respiratory tract infection in 1 (6%) and
cytomegalovirus infection in 1 (6%); fungal infection comprised
Candida albicans CLABSI in 1 (6%) and Candida parapsilosis CLABSI
in 1 (6%); bacterial infection was represented by Acinetobacter
baumanii bacteremia in 2 (11%) and pneumonia in 1 (6%),
Corynebacterium CLABSI in 2 (11%), Micrococcus CLABSI in 1 (6%),
Pseudomonas aeruginosa pneumonia in 1 (6%), methicillin-sensitive
Staphylococcus aureus CLABSI in 1 (6%), Alpha-hemolytic Streptococ-
cus bacteremia in 1 (6%). Patients may have coexistent viral,
bacterial and fungal infections as well as multiple bacterial or
fungal infections.
(DOC)
Table S2 * CLABSI, central line-associated bloodstream
infection, defined according to Centers for Disease Control and
Prevention; CRBSI, catheter-related bloodstream infection, de-
fined according to Infectious Disease Society of America (10);
CVC, central venous catheter; peri, peripheral; NA, not available.
CVC values indicate blood for culture collected from CVC; peri
values indicate blood for culture collected from peripheral vessel.
All 16 patients did not have another focus of infection such as
pneumonia or skin lesions (All patients had normal chest x-ray or/
and CT scan of the chest at the time of enrollment).
(DOC)
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